Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.19.2
SEGMENT INFORMATION (Tables)
9 Months Ended
Jul. 31, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

For the Nine Months Ended

July 31,

2019

2018

Net loss:

Cancer Diagnostics

$

(4,024,785)

$

(3,783,854)

Cancer Therapeutics

(4,807,668)

(4,583,070)

Patent licensing

 

(875,138)

 

(484,640)

Total

$

(9,707,591)

$

(8,851,564)

Operating costs and expenses excluding non-cash

    share based compensation expense:

Cancer Diagnostics

$

1,953,760

$

1,692,865

Cancer Therapeutics

2,084,694

1,807,515

Patent licensing

 

1,070,408

 

1,266,448

Total

$

5,108,862

$

4,766,828

Operating costs and expenses excluding non-cash

    share based compensation expense

$

5,108,862

$

4,766,828

Plus non-cash share-based compensation expense

 

4,902,512

 

5,227,016

Total operating costs and expenses

$

10,011,374

$

9,993,844

For the Three Months Ended

July 31,

2019

2018

Net loss:

Cancer Diagnostics

$

(917,363)

$

(2,359,568)

Cancer Therapeutics

(1,203,468)

(2,901,708)

Patent licensing

 

(45,217)

 

(332,300)

Total

$

(2,166,048)

$

(5,593,576)

 

 

Operating costs and expenses excluding non-cash 

    share based compensation expense:

Cancer Diagnostics

$

507,356

$

569,512

Cancer Therapeutics

801,704

359,006

Patent licensing

 

44,454

 

411,453

Total

$

1,353,514

$

1,339,971

Operating costs and expenses excluding non-cash

    share based compensation expense

$

1,353,514

$

1,339,971

Plus non-cash share-based compensation expense

 

830,898

 

4,628,333

Total operating costs and expenses

$

2,184,412

$

5,968,304

July 31,

2019

October 31,

2018

Total assets:

Cancer Diagnostics

$

3,201,233

$

2,545,803

Cancer Therapeutics

3,279,496

2,157,359

Patent licensing

 

361,977

 

1,745,380

Total

$

6,842,706

$

6,448,542